[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Bagnato A, Spinella F, Rosanò L: The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol; 2008 Aug;86(8):473-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy.
  • The endothelin (ET) axis, which includes ET-1, ET-2, ET-3, and 2 G protein-coupled receptor subtypes, ET AR and ET BR, promotes growth and progression of a variety of tumors, such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, lung, bladder, endometrial carcinoma, Kaposi's sarcoma, brain tumors, and melanoma.
  • Acting on selective receptors, ET-1 regulates mitogenesis, cell survival, angiogenesis, bone remodeling, stimulation of nociceptors, tumor-infiltrating immune cells, epithelial-to-mesenchymal transition, invasion, and metastatic dissemination.
  • At the molecular level, endothelin receptor antagonists, besides providing ideal tools for dissecting the ET axis, have demonstrated their potential in developing novel therapeutic strategies.
  • Emerging experimental and clinical data demonstrate that interfering with endothelin receptors provides an opportunity for the development of rational combinatorial approaches using endothelin receptor antagonists in combination with chemotherapy or molecularly targeted therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Endothelins / genetics. Neoplasms / drug therapy. Neoplasms / genetics
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Angiogenesis Inhibitors / therapeutic use. Animals. Endothelin-1 / biosynthesis. Humans. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / pathology. Receptors, Endothelin / drug effects. Receptors, Endothelin / genetics. Receptors, Endothelin / physiology. Signal Transduction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758494.001).
  • [ISSN] 0008-4212
  • [Journal-full-title] Canadian journal of physiology and pharmacology
  • [ISO-abbreviation] Can. J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Endothelin-1; 0 / Endothelins; 0 / Receptors, Endothelin
  • [Number-of-references] 87
  •  go-up   go-down


2. Reich O, Regauer S: Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol; 2007 Jul;19(4):347-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormonal therapy of endometrial stromal sarcoma.
  • PURPOSE OF REVIEW: Low-grade endometrial stromal sarcomas are steroid receptor positive tumors with slow tumor progression and high recurrence rates, which lack established treatment protocols.
  • We present an update on hormonal therapy options.
  • RECENT FINDINGS: In the past, hormonal therapy consisted of progestins for advanced/recurrent/metastatic low-grade endometrial stromal sarcomas.
  • Aromatase inhibitors and gonadotropin-releasing hormone analogues have become new effective alternatives for first and second line treatment.
  • The high recurrence rates after short disease free intervals in low-grade endometrial stromal sarcoma patients were partly due to inadvertent growth stimulation during estrogen-containing hormone replacement therapy and tamoxifen treatment, which - according to current knowledge - are contraindicated.
  • Recently, hormonal therapy has been introduced for the prevention of recurrences.
  • Aromatase inhibitors are becoming the treatment of choice, since progestins are poorly tolerated due to side effects.
  • The effective duration of preventive hormonal therapy is still undetermined.
  • SUMMARY: Hormonal therapy with progestins, aromatase inhibitors and gonadotropin-releasing hormone analogues has become an effective treatment alternative to radiation and chemotherapy for low-grade endometrial stromal sarcoma patients.
  • Preventive hormonal therapy is of particular interest in the setting of concomitant endometriosis.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Aromatase Inhibitors / therapeutic use. Female. Goserelin. Humans. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545798.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 50
  •  go-up   go-down


3. Spano JP, Soria JC, Kambouchner M, Piperno-Neuman S, Morin F, Morere JF, Martin A, Breau JL: Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol; 2003;20(1):87-93
Hazardous Substances Data Bank. AMINOGLUTETHIMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma.
  • Endometrial stromal sarcoma (ESS) is a rare neoplasm, mainly observed in premenopausal women.
  • We describe two women 44 and 34 years old at the time ESS diagnosis, who developed lung metastases 3 and 6 years, respectively, after initial treatment: hysterectomy without (case 1) or with oophorectomy (case 2), followed by hormone replacement therapy (HRT) for the latter.
  • Their estrogen (ER) and progesterone receptors (PR) were analyzed biochemically in metastatic lung tissue, yielding respective concentrations of ER 242 and 184, and PR 910 and 100 fmol/mg of cytosol protein.
  • Both patients started treatment with the aromatase inhibitor aminoglutethimide (500 mg qid) after surgery for the first patient and after stopping HRT for the second.
  • Under aromatase-inhibitor therapy, both patients achieved a complete response, patient 1 remains disease- free with 14+ years of follow-up, and patient 2 with 7+ years.
  • Our data suggest that an aromatase inhibitor may be an effective treatment for ESS.
  • Furthermore, routine ER and PR analyses could be useful to predict the response to hormonal therapy in ESS.
  • [MeSH-major] Aminoglutethimide / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / secondary
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Disease-Free Survival. Enzyme Inhibitors / therapeutic use. Female. Humans. Hysterectomy. Ovariectomy. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Obstet Gynaecol. 1996 Dec;103(12):1252-4 [8968246.001]
  • [Cites] Gynecol Oncol. 1987 Jan;26(1):87-97 [3792939.001]
  • [Cites] Rev Mal Respir. 2001 Sep;18(4 Pt 1):440-2 [11547255.001]
  • [Cites] Cancer Treat Rev. 1984 Sep;11(3):189-204 [6241038.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):458-60 [9887250.001]
  • [Cites] Obstet Gynecol. 1968 Jan;31(1):33-9 [5635843.001]
  • [Cites] Surg Gynecol Obstet. 1965 Sep;121:531-7 [14332889.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(5-6):379-82 [10609499.001]
  • [Cites] Gynecol Oncol. 1985 Jan;20(1):120-8 [3965374.001]
  • [Cites] Obstet Gynecol. 1977 Apr;49(4):393-403 [854242.001]
  • [Cites] Obstet Gynecol. 1962 Jul;20:23-35 [13871981.001]
  • [Cites] Virchows Arch. 1994;425(5):541-5 [7850080.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):453-61 [9469328.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):384-8 [11531300.001]
  • [Cites] Gynecol Oncol. 1983 Jun;15(3):305-15 [6862290.001]
  • [Cites] Clin Radiol. 1975 Jan;26(1):99-101 [804373.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2620-35 [11555572.001]
  • [Cites] Cancer. 1977 Aug;40(2):898-906 [890670.001]
  • [Cites] Pathol Res Pract. 1996 Mar;192(3):215-23 [8739468.001]
  • [Cites] Am J Obstet Gynecol. 1986 Jul;155(1):95-101 [2942037.001]
  • (PMID = 12665689.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Enzyme Inhibitors; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0O54ZQ14I9 / Aminoglutethimide
  •  go-up   go-down


Advertisement
4. Garavaglia E, Pella F, Montoli S, Voci C, Taccagni G, Mangili G: Treatment of recurrent or metastatic low-grade endometrial stromal sarcoma: three case reports. Int J Gynecol Cancer; 2010 Oct;20(7):1197-200
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent or metastatic low-grade endometrial stromal sarcoma: three case reports.
  • BACKGROUND: The treatment of recurrent or metastatic low-grade endometrial stromal sarcoma (LG-ESS) is still controversial.
  • Responses to hormonal therapy have been reported, because of the presence of estrogen and progestin receptors.
  • Also chemotherapy has been used, but the percentage of response is low.
  • The second patient developed pelvic and abdominal recurrences, managed by surgery, 33 months after primary treatment and a subsequent lung recurrence 11 years later.
  • They all presented regression or stabilization of metastatic lesions.
  • CONCLUSIONS: In LG-ESS, the combined treatment of surgery and progestin therapy is effective in achieving both local and distant disease control.
  • Metastatic lesions, especially pulmonary lesions, seem to benefit from surgical removal, followed by progestin therapy.
  • Hormonal therapy should be maintained for an indefinite period.
  • On account of the long period existing between primary tumor and recurrent disease, a long-term follow-up is always recommended after the primary treatment.
  • [MeSH-major] Endometrial Neoplasms / surgery. Endometrial Stromal Tumors / surgery. Hysterectomy. Neoplasm Recurrence, Local / surgery. Sarcoma, Endometrial Stromal / surgery
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495227.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, Dörken B, Reichardt P: Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol; 2006 Jun;101(3):464-9
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
  • Endometrial stromal sarcoma (ESS) is a rare disease with probably less than 700 new cases in the US or EU per year.
  • A higher risk in women receiving estrogen replacement therapy (ERT) or tamoxifen has been suspected, and remissions following treatment with progestins have been reported in case studies.
  • Aromatase inhibitors represent an interesting new treatment option.
  • We therefore conducted a retrospective study to evaluate the influence of hormonal treatment to ESS.
  • METHODS: Our institutional sarcoma data bank was screened for cases of ESS since 1999.
  • 5/10 patients were on ERT and 3/10 on tamoxifen at the time of diagnosis of metastatic disease.
  • Treatment strategies consisted of stopping ERT and tamoxifen, respectively, or initiation of the progestin MPA or letrozole.
  • 2/3 patients responded to MPA as first-line treatment (1 CR; 50+ months, 1 PR; 9 months).
  • 4/5 patients responded to letrozole as first-line therapy (3 PR;3+, 9+ and 10+ months) or second-line treatment after MPA (1 PR; 37+ months).
  • Survival since diagnosis of metastatic disease is 4 to 164 months.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Stromal Tumors / drug therapy. Estrogen Replacement Therapy / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Humans. Medroxyprogesterone Acetate / adverse effects. Medroxyprogesterone Acetate / therapeutic use. Middle Aged. Nitriles / adverse effects. Nitriles / therapeutic use. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Retrospective Studies. Tamoxifen / adverse effects. Tamoxifen / therapeutic use. Triazoles / adverse effects. Triazoles / therapeutic use. Uterine Neoplasms / drug therapy. Uterine Neoplasms / surgery

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2006 Aug;102(2):413-4; author reply 414 [16712906.001]
  • (PMID = 16368128.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 7LKK855W8I / letrozole; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


6. Bréchot JM, Kamboucher M, Brauner M, Destable MD, Duperron F, Morère JF: [Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy]. Rev Mal Respir; 2007 Jan;24(1):69-72
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy].
  • INTRODUCTION: Low grade endometrial stromal sarcoma (ESS) often expresses oestrogen (ER) and progesterone (PR) receptors, even in metastatic disease.
  • CASE REPORT: Two years after the institution of oestrogen replacement therapy (HRT) a woman of 56 presented with haemoptysis which led to the discovery of multiple pulmonary nodules.
  • Twelve years previously the patient had had a hysterectomy for a low grade endometrial stromal sarcoma, ER and PR positive.
  • Surgical resection of the nodules on the right side confirmed the diagnosis of metastatic endometrial stromal sarcoma.
  • Three months after the withdrawal of HRT and treatment with an aromatase inhibitor (letrozole) the contralateral metastases had disappeared and this complete response was maintained for more than 2 years of follow-up.
  • Hormonal treatment with aromatase inhibitors may be considered in cases where ER and PR are expressed by the primary tumour and metastases, with possible benefits even in metastatic disease.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Nitriles / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / secondary. Triazoles / therapeutic use. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268368.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


7. Ishibashi M, Nakayama K, Shamima Y, Katagiri A, Iida K, Nakayama N, Miyazaki K: [Two cases of endometrial stromal sarcoma (ESS) in which survival was prolonged by administration of MPA]. Gan To Kagaku Ryoho; 2008 May;35(5):857-61
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of endometrial stromal sarcoma (ESS) in which survival was prolonged by administration of MPA].
  • Endometrial stromal sarcoma (ESS) is very rare.
  • MPA is one effective hormonal treatment for ESS.
  • We describe two cases in which patients with metastatic low-grade ESS lesions had prolonged survival with MPA therapy.
  • Case 1 was a 50-year-old woman with a low-grade uterine endometrial stromal tumor who had been operated on at another hospital.
  • She had an incomplete response to chemotherapy.
  • We initiated MPA therapy, which resulted in significant improvement in her metastatic lesions.
  • Following surgery (TAH+BSO), MPA therapy was initiated and she had no recurrence.
  • She was treated with chemotherapy, MPA and radiotherapy.
  • Her metastases improved, and the patient has continued to survive on MPA therapy alone.
  • These cases suggest that MPA might be an effective hormonal therapy for patients with low-grade ESS.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Medroxyprogesterone Acetate / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487930.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


8. Lin JF, Slomovitz BM: Uterine sarcoma 2008. Curr Oncol Rep; 2008 Nov;10(6):512-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine sarcoma 2008.
  • Uterine sarcomas are a group of rare and usually aggressive soft tissue cancers.
  • The three major subtypes of uterine sarcomas (listed in decreasing order of incidence) are carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma.
  • Surgery--including hysterectomy and resection of disease--serves as the main treatment modality.
  • Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas' rare and aggressive nature.
  • For patients with metastatic recurrent disease, aggressive therapy is limited by low response rates and limited duration of response.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / therapy
  • [MeSH-minor] Carcinosarcoma / diagnosis. Carcinosarcoma / therapy. Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Female. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / therapy. Medical Oncology / methods. Neoplasm Metastasis. Recurrence. Research Design. Treatment Outcome

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 Feb 15;112(4):820-30 [18189292.001]
  • [Cites] Obstet Gynecol. 1986 Mar;67(3):417-24 [3945454.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):513-7 [17935762.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):939-44 [9625851.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):526-31 [17290061.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):270-94 [8001001.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):70-5 [9345359.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):176-86 [12833470.001]
  • [Cites] Gynecol Oncol. 2008 Jul;110(1):43-8 [18445505.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):535-58 [8179071.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(4):370-4 [17009628.001]
  • [Cites] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1200-1 [18217961.001]
  • [Cites] Gynecol Oncol. 1998 Jan;68(1):8-13 [9454652.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):323-8 [18394689.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2170-82 [7127257.001]
  • [Cites] Arch Gynecol Obstet. 2002 Apr;266(2):92-5 [12049303.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Obstet Gynecol. 1994 Jun;83(6):1015-20 [8190416.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):25-32 [8690287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):739-48 [11172957.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(6):541-6 [10215437.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):821-7 [9311600.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2239-47 [3179938.001]
  • [Cites] Adv Anat Pathol. 2000 Sep;7(5):257-81 [10976906.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):47-52 [10219793.001]
  • [Cites] Hum Pathol. 1990 Feb;21(2):223-7 [2307449.001]
  • [Cites] Obstet Gynecol. 1994 Mar;83(3):414-8 [8127535.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1972-9 [9806656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Dec;12(12):2127-30 [3793549.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):204-8 [15047237.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):370-5 [7705670.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):253-7 [9648597.001]
  • [Cites] Br J Radiol. 1993 Nov;66(791):1009-15 [8281375.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):630-4 [17320937.001]
  • [Cites] Hum Pathol. 1970 Sep;1(3):331-49 [4330001.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):369-73 [7997731.001]
  • [Cites] Cancer. 1978 Sep;42(3):1161-70 [698911.001]
  • [Cites] Gynecol Oncol. 1996 Nov;63(2):247-53 [8910635.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):313-5 [18534248.001]
  • (PMID = 18928666.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


9. Bosincu L, Massarelli G, Cossu Rocca P, Isaac MA, Nogales FF: Rectal endometrial stromal sarcoma arising in endometriosis: report of a case. Dis Colon Rectum; 2001 Jun;44(6):890-2
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal endometrial stromal sarcoma arising in endometriosis: report of a case.
  • PURPOSE: Endometriosis of the rectovaginal septum can harbor different types of secondary tumors that may involve the rectal wall and protrude into its lumen, thus making diagnosis difficult.
  • Extrauterine low-grade endometrial stromal sarcoma may rarely arise in endometriosis.
  • Concomitant peritoneal nodules and a metastatic paracolic lymph node were also found.
  • Histopathologically, primary endometriotic foci were found in close relationship with an endometrial stromal sarcoma which invaded the rectal wall.
  • The patient was treated by surgery and subsequent chemotherapy and was alive and well 20 months later.
  • [MeSH-major] Endometrial Neoplasms / etiology. Endometriosis / complications. Sarcoma / etiology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11391154.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Yokoyama Y, Ono Y, Sakamoto T, Fukuda I, Mizunuma H: Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection. Gynecol Oncol; 2004 Mar;92(3):999-1001
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection.
  • BACKGROUND: The endometrial stromal sarcoma (ESS) is a rare neoplasm of the uterine origin.
  • A case of a patient who successfully underwent surgical extraction of metastatic tumors of the low-grade ESS in the right ventricle is described in the present report.
  • The chemotherapy was effective against the recurrent tumors except for intracardiac site.
  • [MeSH-major] Endometrial Neoplasms / pathology. Heart Neoplasms / secondary. Heart Neoplasms / surgery. Sarcoma, Endometrial Stromal / secondary. Sarcoma, Endometrial Stromal / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14984976.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Nakayama K, Ishikawa M, Nagai Y, Yaegashi N, Aoki Y, Miyazaki K: Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate. Int J Clin Oncol; 2010 Apr;15(2):179-83
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate.
  • BACKGROUND: The aim of this study was to investigate the usefulness of medroxyprogesterone acetate (MPA) therapy for patients with metastatic low-grade endometrial stromal sarcoma (LGESS).
  • METHODS: A retrospective review was performed of five patients with metastatic LGESS lesions in whom MPA therapy prolonged survival.
  • Three of the five patients received several types of chemotherapy, and all of these patients received the same MPA (200-600 mg/day) hormonal therapy.
  • The median overall survival from the time of recurrence was 41 months (range, 9-163 months).
  • CONCLUSION: The patients in this study demonstrate that MPA treatment may extend the survival of patients with LGESS that is metastatic to the lung.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Medroxyprogesterone Acetate / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Ovariectomy. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1987 Jan;26(1):87-97 [3792939.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1888-93 [7116313.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1084-9 [18179547.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):458-60 [9887250.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):749-54 [12445254.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):37-43 [12821339.001]
  • [Cites] Cancer Lett. 2001 Jun 10;167(1):39-48 [11323097.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):567-71 [15297205.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):170-6 [12821359.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2798-803 [17602085.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):35-9 [2354406.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 May;35(5):857-61 [18487930.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):769-71 [15582003.001]
  • [Cites] Gynecol Oncol. 1985 Jan;20(1):120-8 [3965374.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):464-9 [16368128.001]
  • [Cites] Cancer. 1966 Jun;19(6):755-66 [5939046.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):384-8 [11531300.001]
  • [Cites] Obstet Gynecol. 1984 Aug;64(2):173-8 [6738952.001]
  • [Cites] Obstet Gynecol. 2008 Nov;112(5):1102-8 [18978112.001]
  • [Cites] Am J Clin Pathol. 1992 Mar;97(3):381-6 [1371902.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):243-5 [16054205.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Aug 15;109(2):209-13 [12860344.001]
  • [Cites] Int J Gynecol Cancer. 2009 Feb;19(2):253-6 [19396004.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):275-8 [2807024.001]
  • [Cites] Med Oncol. 2003;20(1):87-93 [12665689.001]
  • (PMID = 20217451.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


12. Gibbon D, Wagreich A, Nieves-Neira W, Shih W, Ziang W, Rodriguez-Rodriguez L, Germino J: A retrospective review of metastatic or recurrent uterine sarcomas treated with paclitaxel, carboplatin, and gemcitabine chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):5143

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of metastatic or recurrent uterine sarcomas treated with paclitaxel, carboplatin, and gemcitabine chemotherapy.
  • : 5143 Background: The prognosis of metastatic uterine sarcoma is poor with median survival reported between 4-26 months.
  • The primary objective of this study was to assess the activity of paclitaxel, carboplatin and gemcitabine (GCP) in the treatment of primary, metastatic, or recurrent uterine sarcomas.
  • The efficacy of the GCP regimen in women with metastatic or recurrent uterine sarcomas was assessed.
  • Patients were treated on a phase II soft tissue sarcoma protocol or off protocol by the gynecologic oncology division.
  • 4 patients were inevaluable; 3 patients for less than one month of therapy and 1 patient without measurable disease.
  • Histology included 6 leiomyosarcomas (LMS), 1 endometrial stromal sarcoma (ESS), and 2 carcinosarcomas (CS).
  • Median time to progression for all patients was 10 months (95% CI {83 -530 days}).
  • CONCLUSIONS: GCP combination chemotherapy demonstrates moderate activity, with acceptable toxicity, in patients with advanced uterine sarcomas.
  • Given the durable median time to progression and overall survival, this pilot data supports the evaluation of this regimen in a multi-institutional phase II study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016800.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. von Mehren M, Chu Q, Alcindor T, Townsley C, Thallury S, MacAlpine K, Wright JJ, Oza A: Early results of a PMH Phase II Consortium trial of AZD0530 in advanced soft tissue sarcoma (STS). J Clin Oncol; 2009 May 20;27(15_suppl):10579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early results of a PMH Phase II Consortium trial of AZD0530 in advanced soft tissue sarcoma (STS).
  • Advanced STS have limited therapeutic options; therefore we tested the efficacy of AZD0530 in advanced STS.
  • Patients with measurable advanced STS with up to one prior chemotherapy for metastatic disease were eligible for study participation following informed consent.
  • Patients were excluded for cardiac dysfunction, poorly controlled hypertension, inability to swallow or absorb medication.
  • Patients had pulmonary function tests at baseline that were repeated within the first 4 weeks of therapy.
  • RESULTS: 17 patients (11 F, 6M) with advanced STS (leiomyosarcoma 5, rhabdomyosarcoma 3, MFH/carcinosarcoma/Fibrosarcoma 2, endometrial stromal sarcoma/liposarcoma/non-rhabdoSTS 1 each) were enrolled, the majority of whom had prior therapy (14 chemo and 9 xrt).
  • Nine discontinued therapy for progressive disease, 2 for toxicity and 1 patient request.
  • Median time to progression in the 13 patients was 1.7 months.
  • No drug related pulmonary toxicity has been observed.
  • Further testing may be warranted in selected tumors in combination with chemotherapy given pre-clinical synergy data or in tumors pre-selected for target expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Ihnen M, Mahner S, Jänicke F, Schwarz J: Current treatment options in uterine endometrial stromal sarcoma: report of a case and review of the literature. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):957-63
Genetic Alliance. consumer health - Uterine sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment options in uterine endometrial stromal sarcoma: report of a case and review of the literature.
  • Endometrial stromal sarcoma (ESS) accounts for 0.2% of all gynecological malignancies.
  • Forms of possible treatment include surgery, radiotherapy, chemotherapy, and endocrine treatment.
  • Randomized trials analyzing these treatment options are limited due to the rarity of this disease; therefore, a standard therapy could not be established thus far.
  • To present an overview of the current treatment options of ESS, a search of Medline, Embase, and the Cochrane Library was performed and the results concluded.
  • Initial treatment with tamoxifen and local perfusion with cisplatin resulted in disease progression and were discontinued.
  • A novel, therapeutic approach using two cycles of combination chemotherapy with doxorubicin and ifosfamide followed by surgery was applied.
  • Thus, we conclude that although there is no data from randomized trials available, chemotherapy in advanced or metastatic ESS can provide an opportunity for surgical treatment and can lead to long-term remission.
  • [MeSH-major] Endometrial Neoplasms / therapy. Sarcoma, Endometrial Stromal / therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17359294.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


15. Leunen K, Amant F, Debiec-Rychter M, Croes R, Hagemeijer A, Schoenmakers EF, Vergote I: Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation. Gynecol Oncol; 2003 Oct;91(1):265-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation.
  • BACKGROUND: Although the clinical picture of endometrial stromal sarcoma (ESS) is variable, it was never reported to present as a postpartum hemorrhage.
  • In addition, ESS is a tumor type of which, due to its rarity, little is known regarding chemosensitivity and genetic changes.
  • At laparotomy, the invasion of nervous and vascular pelvic structures rendered her inoperable, and chemotherapy (doxorubicin 50 mg/m(2) for 15 min; ifosfamide 5 g/m(2)/24 h; mesna 5 g/m(2), every 3 weeks) was initiated.
  • The ESS appeared to be chemosensitive because after three treatment cycles the tumor iliac metastase significantly decreased in volume and became surgically removable.
  • Three additional courses of chemotherapy and pelvic irradiation were administered.
  • Cytogenetic evaluation of both the primary as well as the metastatic lesions revealed a t(10;17)(q22;p13) as the sole cytogenetic abnormality.
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 17 / genetics. Endometrial Neoplasms / genetics. Postpartum Hemorrhage / etiology. Sarcoma, Endometrial Stromal / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14529693.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Akçay MN: Metastatic disease in the breast. Breast; 2002 Dec;11(6):526-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic disease in the breast.
  • However, metastatic involvement of the breast is relatively rare.
  • Metastatic disease of the breast is therefore often an unexpected diagnosis in a female patient presenting with a breast mass.
  • Of solid tumors at other sites, the most common cancers to metastasize to the breast are, in declining order of frequency, malignant melanoma, lymphoma, lung cancer, ovarian carcinoma, soft tissue sarcoma, and gastrointestinal and genitourinary tumors.
  • Besides these, metastases from osteosarcoma, thyroid neoplasms, and cervical, vaginal and endometrial carcinomas to the breast have been sporadically reported in the literature.
  • In recent reports, particular importance has been attached to the performance of fine-needle aspiration cytology diagnosis, to differentiate a metastasis from a second primary tumor, thus making it possible to avoid unnecessary mastectomy and ensure that appropriate chemotherapy and radiotherapy are implemented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14965721.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


17. Kanjeekal S, Chambers A, Fung MF, Verma S: Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol; 2005 May;97(2):624-37
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for advanced uterine sarcoma: a systematic review of the literature.
  • OBJECTIVE: To conduct a systematic review of the literature regarding the systemic treatment of advanced uterine sarcoma and provide an evidence-based summary of the available literature.
  • "Uterine sarcoma," "leiomyosarcoma," "mixed mesodermal tumor," "chemotherapy," and "systemic therapy" were combined with the search terms for study designs.
  • In a randomized trial of doxorubicin versus doxorubicin plus cyclophosphamide for advanced or recurrent uterine sarcoma, doxorubicin produced an overall response rate (RR) of 19% and median survival of 11.6 months, which was similar to the response with combination chemotherapy (RR 19%, median survival 10.9 months).
  • A randomized trial comparing ifosfamide plus cisplatin versus ifosfamide alone in mixed mesodermal tumors showed a significant improvement in RR and progression-free survival with the combination compared with ifosfamide alone, however, the combination was associated with increased toxicity including death.
  • A randomized trial comparing doxorubicin to doxorubicin with dacarbazine in women with advanced or recurrent uterine sarcoma demonstrated a significantly higher RR with the combination (P < 0.05), but no significant difference in survival.
  • CONCLUSIONS: Offering palliative chemotherapy to patients with advanced, unresectable uterine sarcoma who are symptomatic from this disease is a reasonable decision.
  • Doxorubicin is an option for women with advanced uterine sarcoma.
  • The combination of cisplatinum and ifosfamide is also an option for women with metastatic mixed mesodermal tumors; however, this combination is associated with significant toxicity when compared to ifosfamide alone.
  • [MeSH-major] Mixed Tumor, Mesodermal / drug therapy. Sarcoma, Endometrial Stromal / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials, Phase II as Topic. Female. Humans. Leiomyosarcoma / drug therapy. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863170.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


18. Woytoń J, Florjański J, Tomiałowicz M: [Stromal sarcoma in pregnancy--a case report]. Ginekol Pol; 2002 Apr;73(4):400-3
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stromal sarcoma in pregnancy--a case report].
  • After a few weeks the patient developed intensive abdominal pains.
  • A computer tomography scan was done in which apart from swelling of the retroperitoneal lymph nodes, metastatic type changes in the lungs were also observed.
  • In the histopathological examination stromal sarcoma was revealed.
  • In spite of attempts at using chemotherapy and hormonotherapy no positive effect was achieved.
  • Rapid development of the sarcoma led to the death of the patient after 4 months.
  • [MeSH-major] Endometrial Neoplasms. Pregnancy Complications, Neoplastic. Sarcoma, Endometrial Stromal
  • [MeSH-minor] Adult. Cesarean Section. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Postpartum Period. Pregnancy. Retroperitoneal Neoplasms / secondary. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12152294.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


19. Liegl B, Gülly C, Reich O, Nogales FF, Beham A, Regauer S: Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations. Histopathology; 2007 Mar;50(4):448-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.
  • AIMS: To investigate platelet-derived growth factor receptor (PDGFR)alpha and PDGFRbeta expression and a mutational analysis of PDGFRalpha (exons 11, 12, 17 and 18) and PDGFRbeta (exon 12) genes in endometrial stromal sarcomas (ESS).
  • A mutational analysis of PDGFRalpha (exons 11, 12, 17 and 18) and PDGFRbeta (exon 12) genes on frozen metastatic ESS from three patients detected no mutations leading to amino acid changes in the mature protein.
  • CONCLUSIONS: Patients with PDGFRalpha+ ESS may benefit from treatment with tyrosine kinase inhibitors by blocking autocrine and paracrine stimulation loops, blocking neovascularization and enhancing the effects of chemotherapy.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Sarcoma, Endometrial Stromal / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448020.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


20. Benoit L, Arnould L, Cheynel N, Goui S, Collin F, Fraisse J, Cuisenier J: The role of surgery and treatment trends in uterine sarcoma. Eur J Surg Oncol; 2005 May;31(4):434-42
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surgery and treatment trends in uterine sarcoma.
  • The parameters studied were histological type, tumour stage and treatment.
  • The control of pelvic, local and/or metastatic disease were also studied.
  • RESULTS: The histological types consisted in 34 leiomyosarcomas, 25 mixte mullerian tumours, 12 endometrial stromal sarcoma and one angiosarcoma.
  • The percentage of second-line surgery (post-radiotherapy or -chemotherapy) rose from 2.2% in 1966-1989 to 19.2% in 1990-2002.
  • Chemotherapy was administered in 37.5% of cases with also no difference between the two periods.
  • CONCLUSION: Surgery remains the reference treatment.
  • Local and regional disease control, as adjuvant therapies do not seem to decrease the risk of metastatic spread or increase survival.
  • [MeSH-major] Sarcoma / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837053.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Pautier P, Genestie C, Fizazi K, Morice P, Mottet C, Haie-Meder C, Le Cesne A, Lhommé C: Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Int J Gynecol Cancer; 2002 Nov-Dec;12(6):749-54
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
  • There is no standard therapy for cases of relapse, although chemotherapy is commonly used.
  • We studied the use of a cisplatin-based chemotherapy regimen for uterine sarcomas with an unusually long follow-up.
  • Group 1 consisted of patients undergoing adjuvant therapy (for initial disease, eight patients; for pelvic recurrence, two patients); Group 2 consisted of patients with advanced disease (locoregional after initial local therapy, five patients; local recurrence, six patients) or metastatic disease (stage IV, four patients; recurrence, 14 patients).
  • DECAV therapy consisted of doxorubicin 50 mg/m2 d1, dacarbazine (DTIC) 200 mg/m2/d d1-3, vindesine 2 mg/day d1-2, cisplatin 100 mg/m2 d3, and either cyclophosphamide (CPM) 200 mg/m2/d d1-3 (n = 21), or ifosfamide (IFM) 2 g/m2/d d1-3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia (nine patients), including 13 cases of febrile neutropenia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Blood Transfusion. Carcinosarcoma / drug therapy. Carcinosarcoma / mortality. Carcinosarcoma / secondary. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. France. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / mortality. Leiomyosarcoma / secondary. Liver Neoplasms / drug therapy. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Middle Aged. Neoplasm Staging. Neutropenia. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / mortality. Sarcoma, Endometrial Stromal / secondary. Survival Analysis. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445254.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; DECAV protocol
  •  go-up   go-down


22. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D; 2006;7(5):317-28
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The drug is being developed by PharmaMar (Zeltia) in partnership with Johnson & Johnson Pharmaceutical Research & Development LLC.
  • It was synthetically isolated and developed by the University of Illinois and licensed to PharmaMar; the company has completed the hemisynthesis of agent.
  • In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system.
  • Trabectedin blocks the cell cycle at the G(2) phase, while cells at the G(1 )phase are most sensitive to the drug.
  • It also inhibits overexpression of the multidrug resistance-1 gene (MDR-1) coding for the P-glycoprotein that is a major factor responsible for cells developing resistance to cancer drugs.
  • The agent is also thought to interfere with the nucleotide excision repair pathways of cancer cells, suggesting that it could be effective in the treatment of many cancer types including melanoma and sarcoma, as well as lung, breast, ovarian, endometrial and prostate cancers; clinical evaluations are underway in these indications.
  • Ortho Biotech will market the product in the US, Japan and the rest of the world; Tibotec Therapeutics (a division of Ortho Biotech) will commercialise it in the US.
  • PharmaMar will receive an initial payment from Ortho Biotech plus future milestone and royalty payments linked to development targets and sales; the upfront payment would be approximately 20 million US dollars with royalties contributing 10-20% of total sales of the drug.
  • Trabectedin is undergoing clinical trials in soft tissue sarcoma (Sarcoma in the Phase table), ovarian, breast, endometrial, prostate and non-small-cell lung cancers.
  • The US FDA granted trabectedin orphan drug status for ovarian cancer in April 2005.
  • Trabectedin also received orphan drug status from the European Commission for the treatment of ovarian cancer in October 2003.
  • Trabectedin has undergone a phase II study for the second- or third-line treatment of ovarian cancer in Europe (England and Belgium), the US and Canada.
  • The trial was initiated in October 2002 and evaluated a weekly schedule of trabectedin (0.58 mg/m(2)) via IV infusion for 3 weeks followed by a week of rest.
  • A separate phase II trial evaluating the antitumour activity of trabectedin as a second-line therapy in advanced ovarian cancer was conducted by researchers at the Southern Europe New Drugs Organization (SENDO) in Milan, Italy.
  • PharmaMar and Johnson & Johnson are conducting a pivotal (STS-201) trial to compare a weekly and daily dosing regimen of trabectedin among patients with advanced or metastatic soft tissue sarcoma who are unresponsive to standard chemotherapy of doxorubicin and ifosfamide.
  • The randomised, multicentre, open-label trial has completed enrolment of 270 patients during the second quarter of 2005.
  • Positive data from the STS-201 trial have been announced.
  • An independent data monitoring committee has found that interim data supports a positive trend in time to disease progression favouring patients receiving the daily dosing regimen.
  • Final results from the STS-201 trial will form the basis of MAA re-submission with European regulatory authorities.
  • PharmaMar has held a pre-submission meeting with the EMEA and has presented a formal letter of intent to file for approval of trabectedin for soft tissue sarcoma.
  • Previously, PharmaMar first filed for EU registration of trabectedin for treatment of advanced soft tissue sarcoma in November 2001, which was accepted for review by the EMEA and Swiss Health Authorities.
  • Trabectedin was granted orphan drug status in Europe for recurrent soft tissue sarcoma in 2001.
  • It was also granted orphan drug status by the FDA for the same indication in October 2004.
  • Phase I studies are being conducted to evaluate trabectedin in combination with doxorubicin and liposomal doxorubicin for the treatment of soft tissue sarcoma.
  • PharmaMar is also conducting a phase I study of sequential paclitaxel followed by trabectedin in patients with soft tissue sarcoma.
  • At additional dose levels, patients with other tumour types will be enrolled to assess the antitumour activity of the combination.
  • The US NCI has approved and is partially funding a phase I clinical programme to determine the feasibility of using trabectedin to treat children with soft tissue sarcoma and bone sarcoma who are resistant to conventional therapies.
  • Trabectedin has completed phase II studies for small round cell sarcoma and rhabdomyosarcoma, which are aggressive tumours occurring predominantly in children.
  • A phase II study evaluating two dosing schedules of trabectedin has been conducted in patients with leiomyosarcomas or liposarcomas refractory to standard doxorubicin + ifosfamide chemotherapy.
  • [MeSH-minor] Animals. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Humans. Randomized Controlled Trials as Topic. Sarcoma / drug therapy. Urochordata / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922593.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  • [Number-of-references] 56
  •  go-up   go-down


23. Ferraresi V, Ciccarese M, Cercato MC, Nuzzo C, Zeuli M, Di Filippo F, Giannarelli D, Cognetti F: Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. Cancer Chemother Pharmacol; 2008 Dec;63(1):149-55
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
  • PURPOSE: To explore the clinical activity and toxicity of gemcitabine infused at the fixed dose of 10 mg/m(2)/min over 100 min in patients with soft tissue sarcomas (STSs).
  • PATIENTS AND METHODS: Fourteen patients with advanced locally unresectable and/or metastatic, pretreated STSs (seven leiomyosarcoma, three malignant schwannoma, one synovialsarcoma, one malignant fibrous histiocytoma, one endometrial stromal cell sarcoma, one undifferentiated) were treated with gemcitabine 10 mg/m(2)/min/week over 100 min given for 3 weeks out of 4.
  • The median number of previous medical treatments for advanced disease was 1 (range 1-2).
  • Treatment was well tolerated and the main causes of dose-reduction or omission/delay were hematological and liver toxicities.
  • One patient (7%; 95% confidence interval: 0.2-33.9%) with a metastatic uterine leiomyosarcoma obtained a partial response that lasted for 6.5 months.
  • The median time to progression was 3.1 months (range 1.0-9.5).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease Progression. Dose-Response Relationship, Drug. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18351342.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


24. Bagnato A, Rosanò L: The endothelin axis in cancer. Int J Biochem Cell Biol; 2008;40(8):1443-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The endothelin axis, comprising endothelins and their receptors, has recently emerged as relevant player in tumor growth and metastasis by regulating mitogenesis, cell survival, angiogenesis, bone remodeling, stimulation of nociceptor receptor, tumor-infiltrating immune cells, epithelial-to-mesenchymal transition, invasion and metastatic dissemination.
  • Endothelin-1 participates in the growth and progression of a variety of tumors such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, bladder, endometrial carcinomas, Kaposi's sarcoma, brain tumors, melanoma, and bone metastases.
  • This review highlights key signaling pathways activated by endothelin-1 axis in cancer, since the understanding the full spectrum activated by endothelin-1 is critical for the optimal design of targeted therapies.
  • Preliminary experimental and clinical data demonstrate that interfering with endothelin receptor by using endothelin-1 receptor antagonists alone and in combination with cytotoxic drugs or molecular inhibitors could represent a new mechanism-based antitumor strategy.
  • [MeSH-minor] Cell Proliferation / drug effects. Cell Survival / drug effects. Cell Survival / physiology. Endothelin Receptor Antagonists. Female. GTP-Binding Proteins / physiology. Humans. Male. Neoplasm Invasiveness / physiopathology. Neovascularization, Pathologic / physiopathology. Osteogenesis / physiology. Ovarian Neoplasms / drug therapy. Prostatic Neoplasms / drug therapy. Receptor, Endothelin A / physiology. Receptor, Epidermal Growth Factor / physiology. Signal Transduction

  • Guide to Pharmacology. gene/protein/disease-specific - Endothelin receptors - overview and references .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325824.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Endothelin Receptor Antagonists; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptors, Endothelin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.1.- / GTP-Binding Proteins
  • [Number-of-references] 27
  •  go-up   go-down


25. Tzakas E, Liu S, Todd RW, Redman CW: Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS). J Obstet Gynaecol; 2009 Nov;29(8):778-9
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Nitriles / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Triazoles / therapeutic use
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821687.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down






Advertisement